A5003194406- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Renal and related cancers
- vaccines and immunoinformatics approaches
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
Natera (United States)
2023-2024
715 Background: Treatment response monitoring is key to effective disease management for patients with advanced (RCC) and can potentially improve clinical outcomes. Circulating tumor DNA (ctDNA) has shown promise as a biomarker in the early identification of treatment variety types. Herein, we evaluated ctDNA-derived molecular residual (MRD) detection dynamics both clear cell (ccRCC) non-clear (nccRCC) RCC treated standard care therapy provide correlations Methods: This was multi-center...
PURPOSE Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in variety of types, with the potential to improve clinical outcomes. We evaluated ctDNA status and dynamics during surveillance part TRM outcomes both patients clear cell renal carcinoma (ccRCC) non–clear (nccRCC) treated standard-of-care immunotherapy or targeted therapy regimens. METHODS This was multicenter retrospective analysis real-world data obtained from...
Melanoma is a skin cancer, in which cancer cells form the melanocytes. It can occur anywhere on but hard to spot due its only signs being change way specific mole or pigmented area looks. usually curable. Still, once it has bypassed stage IV, become fatal and deadly. The stages of melanoma depend how thick tumor whether broken through skin. most deadly spread numerous parts body, including not limited lungs, liver, brain. Studies have shown that average 5-year survival rate for 94%; however,...